Armata Pharmaceuticals (ARMP) Non-Current Assets (2013 - 2026)
Armata Pharmaceuticals (ARMP) posted Non-Current Assets of $63.9 million for Q1 2026, down 3.56% sequentially from $66.2 million in Q4 2025, and down 13.81% YoY from $74.1 million in Q1 2025.
Armata Pharmaceuticals (ARMP) Non-Current Assets (2013 - 2026) Analysis & Trends
Armata Pharmaceuticals has reported Non-Current Assets for 14 years, with the latest figure at $63.9 million in Q1 2026.
- Quarterly Non-Current Assets fell 13.81% year-over-year to $63.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $275.9 million (down 8.78% YoY) and the FY2025 annual result came in at $66.2 million, down 11.87% from the prior year.
- Non-Current Assets eased to $63.9 million in Q1 2026 per ARMP's latest filing, from $66.2 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $79.2 million in Q4 2023 and troughed at $59.1 million in Q1 2022.
- A 5-year average of $70.8 million and a median of $73.3 million in 2025 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2026: Non-Current Assets jumped 109.3% in 2022, then retreated 13.81% in 2026.
- Over 5 years, Non-Current Assets stood at $68.8 million in 2022, then gained by 15.16% to $79.2 million in 2023, then retreated by 5.15% to $75.1 million in 2024, then retreated by 11.87% to $66.2 million in 2025, then dropped by 3.56% to $63.9 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $63.9 million, $66.2 million, and $72.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.01 Bn | 132.16 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 60.18 Bn | 55.04 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.55 Bn | 28.24 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.36 Bn | - | 18.06 Bn |
| 10 | Armata Pharmaceuticals | 172.13 Mn | 148.13 Mn | - | 62.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 62.79 Mn |
| Mar 31, 2026 | 63.85 Mn |
| Dec 31, 2025 | 66.21 Mn |
| Sep 30, 2025 | 72.59 Mn |
| Jun 30, 2025 | 73.27 Mn |
| Mar 31, 2025 | 74.08 Mn |
| Dec 31, 2024 | 75.13 Mn |
| Sep 30, 2024 | 75.85 Mn |
| Jun 30, 2024 | 77.41 Mn |
| Mar 31, 2024 | 78.64 Mn |
| Dec 31, 2023 | 79.21 Mn |
| Sep 30, 2023 | 76.18 Mn |
| Jun 30, 2023 | 74.38 Mn |
| Mar 31, 2023 | 70.18 Mn |
| Dec 31, 2022 | 68.79 Mn |
| Sep 30, 2022 | 59.64 Mn |
| Jun 30, 2022 | 59.68 Mn |
| Mar 31, 2022 | 59.07 Mn |
| Dec 31, 2021 | 54.77 Mn |
| Sep 30, 2021 | 28.49 Mn |